Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Targetable Gene Dependencies in Ewing Sarcoma Subtypes
FY 2023-24
Summary
Ewing sarcoma (EwS) is the second most common bone cancer, usually affecting adolescents and young adults. It is always caused by an aberrant joining of two genes, most commonly EWSR1 and FL1. With no targeted therapy for this type of cancer, there is a need for finding new drug targets and a thorough characterization of the subtypes of this sarcoma. Previous work suggests that RNA sequencing (RNA-seq)-based analyses can be used to discover new and clinically relevant tumour subtypes, but such approach has not yet been taken for EwS. We have developed computational methods to molecularly classify tumour tissues based on RNA-seq data: RACCOON – an unsupervised hierarchical clustering tool for human cancer and OTTER – a classifier that assigns tumours to classes created by RACCOON. Using these tools, we found that EwS has a unique transcriptional signature among all other cancers, and our subsequent analysis indicated the existence of EwS subtypes. While the protein encoded by the fusion gene exhibits broad effects observed on the single-cell level, it is unknown if the varying levels of its activity underlie the subtypes we observe. Other groups have also shown that targeting genes which are not directly affected by the fusion protein, can pose a therapeutic approach for this cancer. Therefore, we aim to comprehensively classify EwS subtypes and assess their biological and clinical relevance. We will also nominate genes and validate them as potential pan-EwS and subtype-specific drug targets. This approach has the capacity to elucidate the molecular basis of the heterogeneity of EwS, and to improve diagnostic accuracy and treatment strategies, particularly for patients with relapsed tumours and metastases for which current treatment options are limited.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
506226
Name
Pesic Dusan
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Targetable Gene Dependencies in Ewing Sarcoma Subtypes
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bone Cancer; Childhood Cancer; Crispr-Cas9; Drug Targets; Ewing Sarcoma; Fusion Protein; Gene Dependency; Rna Sequencing; Transcriptional Atlas; Tumour Subtype
Abstract
Ewing sarcoma (EwS) is the second most common bone cancer, usually affecting adolescents and young adults. It is always caused by an aberrant joining of two genes, most commonly EWSR1 and FL1. With no targeted therapy for this type of cancer, there is a need for finding new drug targets and a thorough characterization of the subtypes of this sarcoma. Previous work suggests that RNA sequencing (RNA-seq)-based analyses can be used to discover new and clinically relevant tumour subtypes, but such approach has not yet been taken for EwS. We have developed computational methods to molecularly classify tumour tissues based on RNA-seq data: RACCOON – an unsupervised hierarchical clustering tool for human cancer and OTTER – a classifier that assigns tumours to classes created by RACCOON. Using these tools, we found that EwS has a unique transcriptional signature among all other cancers, and our subsequent analysis indicated the existence of EwS subtypes. While the protein encoded by the fusion gene exhibits broad effects observed on the single-cell level, it is unknown if the varying levels of its activity underlie the subtypes we observe. Other groups have also shown that targeting genes which are not directly affected by the fusion protein, can pose a therapeutic approach for this cancer. Therefore, we aim to comprehensively classify EwS subtypes and assess their biological and clinical relevance. We will also nominate genes and validate them as potential pan-EwS and subtype-specific drug targets. This approach has the capacity to elucidate the molecular basis of the heterogeneity of EwS, and to improve diagnostic accuracy and treatment strategies, particularly for patients with relapsed tumours and metastases for which current treatment options are limited.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Pesic, Dusan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~